Abbott Laboratories $ABT Shares Purchased by IFM Investors Pty Ltd

IFM Investors Pty Ltd increased its position in shares of Abbott Laboratories (NYSE:ABT) by 4.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 379,101 shares of the healthcare product maker’s stock after purchasing an additional 15,721 shares during the quarter. IFM Investors Pty Ltd’s holdings in Abbott Laboratories were worth $38,922,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC boosted its position in Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after acquiring an additional 162 shares during the last quarter. United Bank grew its stake in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after acquiring an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC raised its holdings in Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after acquiring an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its holdings in Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after acquiring an additional 292,547 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $90.68 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock has a market capitalization of $157.95 billion, a P/E ratio of 25.40, a PEG ratio of 1.60 and a beta of 0.63. The company has a 50 day moving average price of $88.91 and a 200 day moving average price of $104.84. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the previous year, the company earned $1.09 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

Insider Activity

In other news, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Oppenheimer lowered their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Jefferies Financial Group cut their price target on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday, April 17th. The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Wells Fargo & Company dropped their target price on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, UBS Group reduced their price target on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $118.30.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Wall Street continues to view Abbott as a strong income name, with a TipRanks roundup highlighting ABT as one of three dividend aristocrats currently rated a Strong Buy by analysts. 3 Dividend Aristocrat Stocks Wall Street Loves Right Now — June 30, 2026
• Positive Sentiment: Wells Fargo reiterated its Buy rating on Abbott, reinforcing the view that the stock still has analyst support despite recent volatility. Wells Fargo Remains a Buy on Abbott Laboratories (ABT)
• Positive Sentiment: Abbott’s largest Medical Devices segment is being positioned for a new growth phase, helped by diabetes, heart rhythm, and electrophysiology product momentum. How Abbott’s Largest Segment Is Preparing for the Next Growth Phase
• Neutral Sentiment: News that the U.S. DOJ closed its criminal probe into Abbott’s infant formula plant removes a major legal uncertainty, but reports also say the company is still facing a proposed civil settlement and penalties under the False Claims Act, so the issue is not fully resolved. US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
• Negative Sentiment: Recent market coverage says ABT underperformed in Monday’s session and settled lower, indicating investors were already cautious before the latest news flow. Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.